You are here:

Archived: levetiracetam 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra)

Advice

Following a full submission

levetiracetam (Keppra®) is not recommended for use within NHS Scotland as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.

Levetiracetam has been shown to be non-inferior to carbamazepine controlled-release, the first choice anti-epileptic drug for partial seizures.

However, the manufacturer’s justification of the treatment’s cost in relation to its health benefits was not sufficient to gain acceptance by SMC and they did not present a sufficiently robust economic analysis.

The licence holder has indicated their decision to resubmit.

Drug Details

Drug Name: levetiracetam 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra)
SMC Drug ID: 397/07
Manufacturer: UCB Pharma Ltd
Indication: as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy
BNF Category:
Sub Category: 4.8 Antiepileptic drugs
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 10 September 2007

Current Advice

Resubmission 11 February 2008

Back